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new pathophysiological mechanisms, and performance of
clinical trials in which additive or even synergistic beneficial
effects of treatment with dietary alkalinization and darusen-
tan on progression of renal disease could be demonstrated.
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We thank Dr Bakker, Dr Gans, and Dr Navis for their
interest in our recent KI publication1 linking diet-induced
metabolic acidosis, endothelin receptors, and progressive
nephropathy in the remnant kidney model of chronic
kidney disease (CKD). We agree that our studies support
the need for human studies to examine the effect of source
of dietary protein, rather than the amount of dietary
protein2,3 on progression of CKD. Our earlier studies4
showed that dietary protein as casein that increases
intrinsic acid production induces greater tubulointerstitial
injury in Munich–Wistar rats with intact nephron mass
than dietary protein as soy that does not increase intrinsic
acid production.4 Despite greater tubulointerstitial injury
induced by dietary casein, whole-kidney glomerular
filtration rate (GFR) was not different from the animals
eating dietary soy after 96 weeks.4 Our more recent
publication on which the said investigators comment
shows that dietary casein induced greater GFR decline
than dietary soy after 12 weeks.1 Our earlier study links
tubulointerstitial injury to the increased intrinsic acid
production induced by dietary casein1 and our more
recent study links GFR decline to metabolic acidosis
induced by dietary casein.4 Use of selective endothelin
receptor antagonists support that the tubulointerstitial
injury in the intact kidney1 and GFR decline in the
remnant kidney4 are mediated through endothelin recep-
tors. Together, these data support that dietary casein-
induced increased intrinsic acid production is injurious to
the kidney but that this injury is more likely to lead to GFR
reduction in the remnant than the intact kidney of
Munich–Wistar rats. The investigators apparently agree
with these points.
The investigators question if the data reported1
substantiate our conclusion that casein-induced kidney
injury is mediated by metabolic acidosis and through
endothelin receptors. They state correctly that neither
daily excretion of net acid, NH4
þ , nor total acid was
affected by darusentan, the endothelin A antagonist that
ameliorated tubulointerstitial injury in animals with intact
nephron mass4 and ameliorated GFR decline in remnant
kidneys.1 The investigators also correctly state that
darusentan did not affect the casein-induced systemic
metabolic acidosis in these animals with remnant kidneys.
They agree that the data reported support that darusentan
ameliorates the deleterious effects of dietary casein on GFR
of remnant kidneys but they argue that the data described
above support that these beneficial effects of darusentan
are independent of its effects on metabolic acidosis.
The last sentence of the abstract of our publication1 says
‘Our study suggests that the casein-induced decline in GFR
of the remnant kidney is mediated by metabolic acidosis
through endothelin A receptors’ (italics added). Our point is
that metabolic acidosis induced by dietary casein induces
the injury that leads to GFR decline through endothelin
receptors. We do not state or mean to imply that darusentan
exerts its beneficial effects to ameliorate GFR decline by
reducing metabolic acidosis that then leads to an ameliora-
tion of GFR decline in remnant kidneys as apparently
suggested by the investigators. Instead, we think that our
data support the following scenario: dietary acid increases
intrinsic acid production and metabolic acidosis, leading to
stimulated kidney endothelin production as supported by
increased urine endothelin excretion (Table 4), and the
increased kidney endothelins then cause kidney injury that
reduces GFR through endothelin A receptors.1 We agree
with the investigators that darusentan renders its beneficial
effects independent of metabolic acidosis. The point of our
manuscript, however, is that the described beneficial effects
of endothelin A receptor antagonism provided by darusen-
tan is not by ameliorating metabolic acidosis but instead is
by inhibiting the effects of increased kidney endothelin
activity induced by metabolic acidosis that was in turn
induced by dietary casein. In fact, our earlier studies4,5 show
that increased kidney tubule acidification in remnant
kidneys is mediated through endothelin B, and specifically
not endothelin A, receptors. Consequently, we did not
expect the endothelin A receptor antagonist to affect kidney
acidification and this was indeed the case.1
As stated, we support the call issued by these
investigators to test the hypothesis that the source of
dietary protein can influence the rate of GFR decline in
CKD. Specifically, we hypothesize that diets high in
acid-producing amino acids are associated with faster
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GFR decline than diets low in acid-inducing amino acids.
As Western diets are generally acid-inducing on balance6
and because of the difficulty faced by clinicians in effecting
major diet changes in our patients, we suggest that a more
practical hypothesis to test is whether adding non-food
alkali such as NaHCO3 or Na
þ Citrate to the usual western
diet will slow the rate of GFR decline in CKD subjects
eating a standard western diet. If this intervention slows,
prevents, or stops GFR decline, this would be a compara-
tively inexpensive addition to the armamentarium of
strategies to slow or stop CKD progression toward
complete kidney failure.
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Does chemical structure of
Gd-containing contrast agents
contribute to mortality in
nephrogenic systemic fibrosis?
Kidney International (2008) 74, 1627; doi:10.1038/ki.2008.527
To the Editor: I read with great interest the article by
Swaminathan et al.1 presenting the importance of high
mortality in nephrogenic systemic fibrosis (NSF) and
providing evidence that the short survival of these patients
could be attributed to metal accumulation (gadolinium,
aluminum, iron) in several inner organs, including heart and
blood vessels. Although I completely agree with the authors,
who wrote that they ‘ypresent several novel observations’
despite the fact that ‘there are several limitations’,1 some
information is missing. For example, it would be interesting
to know which Gd-containing contrast agents (GCCA) the
patients received, and whether there was a difference in
applied substances in patients who died and who are still
alive.
As previously described, both transmetalation of GCCA
and association with NSF are preferentially observed along
with nonionic linear compounds.2–4 In contrast, macrocyclic
compounds have up to now not been demonstrated as
causing NSF.4
Uncertainty about the chemical nature of GCCA used in
patients who developed NSF and eventually died due to
cardiac and vascular events limits our understanding of the
disease and thus hampers efforts to prevent it.
Furthermore, of the 32 patients with NSF studied, Table 1
presented only data of the 10 patients who died.1 What are
the demographics, and clinical conditions of the 22
remaining patients? In particular, it would be very interesting
to know whether these two groups were different in some
aspect.
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